12 November 2018
Bioanalysis Rising Star Award 2018 winner announced
Bioanalysis Zone, the knowledge hub for the bioanalytical industry, has named Jing Tu (PPD; VA, USA) the 2018 winner of the newly named Bioanalysis Rising Star Award (BRSA; formerly the New Investigator Award).
The BRSA recognizes and promotes the work of talented new researchers and is awarded annually by Bioanalysis Zone, an online resource for the bioanalytical community, and Bioanalysis, a leading international journal covering the latest scientific, technical and regulatory developments relevant to bioanalysts.
This year’s winner, Jing, a senior group leader in the company’s biomarker lab in Richmond, Virginia, was nominated by Patrick Bennett, Vice President of PPD® Laboratories, in recognition of her work dedicated to biomarker ligand binding assays (LBA) method development, validation and qualification. Pat remarked: “Jing has consistently shown an extremely high level of leadership and strong technical capabilities for PPD Laboratories. She has led the integration of new technologies and implemented a systematic LBA biomarker method development strategy that significantly improved quality, method consistency and method development efficiency.”
On receiving the award, Jing commented: “I am very excited, honored and happy to be selected as the winner of the BRSA this year. I am grateful to the award sponsors – Waters Corporation and Bioanalysis Zone– and to PPD and all the voters for their support.”
As the winner of the BRSA, Jing will present her work at the European Bioanalysis Forum (EBF) 11th Open Symposium in Barcelona, Spain on 22 November 2018. She also receives a 1-year subscription to Bioanalysis and US $1000 courtesy of award sponsor Waters Corporation (MA, USA), a provider of laboratory solutions and software in separations science, mass spectrometry and thermal analysis.
Kim Haynes, Principal Product Marketing Manager (Waters Corporation), who served as a judge for the award commented: “I am honored to be a part of this year’s BRSA. There are such a large number of scientists and researchers doing high quality work with meaningful implications for the future of bioanalysis. It is important to recognize these individuals for their achievements and contributions to the field. This award is a fantastic way to shine a light on these individual accomplishments.”
Naamah Maundrell, Senior Editor of Bioanalysis Zone, added: “It has been a privilege to coordinate this year’s award and a joy to get to know hugely talented bioanalysts from all over the world. I would like to congratulate Jing and all of this year’s nominees for their inspiring research. May their bioanalytical contributions continue!”
Jing won the public vote after three finalists were shortlisted by the judges. The finalists included Buyun Chen (Genentech; CA, USA) and Lisa O’Callaghan (Merck; PA, USA). Videos introducing the research of each finalist are available to view at www.bioanalysis-zone.com.
Nominations are now being accepted for the 2019 Bioanalysis Rising Star Award – contact the Senior Editor Naamah Maundrell directly (email@example.com).
Further details on the EBF 11th Open Symposium can be found here.
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 11,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, peer-reviewed research, exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.